

Please type a plus sign (+) inside this box.

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0751-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number 09/644,668
Filing Date August 24, 2000
First Named Inventor Korman, Alan J.
Group Art Unit 1632 LC44
Examiner Name Unassigned
Attorney Docket Number 014643-010510US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JMR	1	6,162,963		Kucheralapati et al.	12-19-2000	
	2	6,150,584		Kucheralapati et al.	11-21-2000	
	3	6,114,598		Kucheralapati et al.	09-05-2000	
	4	6,075,181		Kucheralapati et al.	06-13-2000	
	5	6,051,227		Allison et al.	04-18-2000	
	6	5,977,318		Linsley et al.	11-02-1999	
	7	5,968,510		Linsley et al.	10-19-1999	
	8	5,939,598		Kucheralapati et al.	11-17-1999	
	9	5,885,796		Lonberg et al.	03-23-1999	
	10	5,877,397		Lonberg et al.	03-02-1999	
	11	5,874,299		Lonberg et al.	02-23-1999	
	12	5,855,887		Allison et al.	01-05-1999	
	13	5,844,095		Linsley et al.	12-01-1998	
	14	5,814,318		Lonberg et al.	09-29-1998	
	15	5,811,097		Allison et al.	09-22-1998	
	16	5,789,650		Lonberg et al.	08-04-1998	
	17	5,770,429		Lonberg et al.	06-23-1998	
	18	5,770,197		Linsley et al.	06-23-1998	
	19	5,661,016		Lonberg et al.	08-26-1997	
	20	5,633,425		Lonberg et al.	05-27-1997	
	21	5,625,126		Lonberg et al.	04-29-1997	
	22	5,569,825		Lonberg et al.	10-29-1996	
JMR	23	5,545,806		Lonberg et al.	08-13-1996	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
JMR	24	PCT	WO00/37504		Hanson et al.	06-29-2000		
JMR	25	PCT	WO00/10383		Tomizuka et al.	03-02-2000		abstract only
JMR	26	PCT	WO98/42752		Kuchroo et al.	10-01-1998		

Examiner
Signature

J. Korman

Date
Considered

8/18/03

¹ EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number 09/644,668
Filing Date August 24, 2000
First Named Inventor Korman, Alan J.
Group Art Unit 1632 1644
Examiner Name Unassigned
Attorney Docket Number 014643-010510US

RECEIVED
OCT 02 2001
FBI CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	27	PCT	WO98/37757		Tomizuka et al.	09-03-1998		abstract only
	28	PCT	WO98/24893	A2	Jakobovits et al.	06-11-1998		
	29	PCT	WO98/24893	A3	Jakobovits et al.	06-11-1998		
	30	PCT	WO98/24884		Lonberg et al.	06-11-1998		
	31	PCT	WO97/07671		Tomizuka et al.	03-06-1997		abstract only
	32	PCT	WO96/34096		Kucherlapati et al.	10-31-1996		
	33	PCT	WO96/33735		Kucherlapati et al.	10-31-1996		
	34	PCT	WO95/33770		Gribben et al.	12-14-1995		
	35	PCT	WO94/25585		Lonberg et al.	11-10-1994		
	36	PCT	WO94/02602		Kucherlapati et al.	02-03-1994		
	37	PCT	WO93/12227		Lonberg et al.	06-24-1993		
	38	PCT	WO92/22645		Huang et al.	12-23-1992		
	39	PCT	WO92/03918		Lonberg et al.	03-19-1992		
DM	40	PCT	WO91/10741		Kucherlapati et al.	07-25-91		

Examiner Signature		Date Considered	8/18/03
-----------------------	--	--------------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box.

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	09/644,668
Filing Date	August 24, 2000
First Named Inventor	Korman, Alan J.
Group Art Unit	4632 1644
Examiner Name	Unassigned
Attorney Docket Number	0146432-010510US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SR	41	BLAIR et al. "Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X _L induction," The J. of Immunology 22:1767 (1998)	
	42	BLUESTONE (1997) J. Immunol. 158:1989-1993	
	43	BRUNET et al., Immunol. Rev. 103-21-36 (1988)	
	44	BRUNET et al., Nature 328:267-270(1987)	
	45	CHAMBERS (1997) Curr. Opin. Immunol. 9:396-404	
	46	CHAMBERS et al., Immunity. 7:885-895(1997)	
	47	CLARK (1986) Human Immunol. 16:100-113	
	48	DAMLE et al., Proc. Natl. Acad. Sci. 78:5096-6001 (1981)	
	49	DARIAVACH et al., Eur. J. Immunol. 18:1901-1905 (1988)	
	50	ELSAS et al. "Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation," J. Exp. Med. 190:355-366 (1999)	
	51	FISHWILD et al. "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus mice," Nature Biotechnology 14:845-851 (1996)	
	52	FREEDMAN (1987) J. Immunol. 138:3260-3267	
	53	FREEMAN (1989) J. Immunol. 143:2714-2722	
	54	GRIBBEN et al. "CTLA4 mediates antigen-specific apoptosis of human T cells," Proc. Natl. Acad. Sci. USA 92:811-815 (1995)	
SM	55	HURWITZ et al. "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma," Proc. Natl. Acad. Sci. USA 95:10067-10071 (1998)	

Examiner
Signature

[Signature]

Date
Considered

8/18/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

Please type a plus sign (+) inside this box.

+



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	09/644,668
Filing Date	August 24, 2000
First Named Inventor	Korman, Alan J.
Group Art Unit	1632 1644
Examiner Name	Unassigned
Attorney Docket Number	0146432-010510US

RECEIVED
OCT 02 2001
PCT CENTER 1600/2300

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

56	HURWITZ et al. "Immunotherapy of primary prostate cancer in a transgenic model using a combination of CTLA-4 blockade and tumor cell vaccine," Cancer Research 60:2444-2448 (2000)
57	KEARNEY (1995) J. Immunol. 155:1032-1036
58	KOHNO et al., Cell. Immunol. 131:1-10 (1990)
59	KRUMMEL et al. "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," (1995) J. Exp. Med. 182:459-465
60	KRUMMEL et al. "CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells," J. Exp. Med 183:2533-2540 (1996)
61	KRUMMEL et al. "Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo," (1996) Int'l Immunol. 8:519-523
62	KWON et al. "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," proc. Natl. Acad. Sci. USA 94:8099-8103 (1997)
63	Lafage-Pochitaloff et al., Immunogenetics 31:198-201 (1990)
64	LEACH et al. "Enhancement of antitumor immunity by CTLA-4 blockade," Science. 271:1734-1736 (1996)
65	LESSLAUER et al., Eur. J. Immunol. 16:1289-1296 (1986)
66	LINDSTEN et al., Science 244:339-343 (1989)
67	LINSLEY et al. "Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes," J Exp. Med. 176:1595-1604 (1992)
68	LINSLEY et al. "CTLA-4 is a second receptor for the B cell activation antigen B7," J. Exp. Med. 174:561-569 (1991)
69	LINSLEY et al., J. Exp. Med. 173:721-730 (1991)
70	LINSLEY et al., Proc. Natl. Acad. Sci. USA 87:5031-5035 (1990)
71	LONBERG et al. "Human antibodies from transgenic mice," International Review of Immunology 13:65-93 (1995)
72	LUHDER (1998) J Exp. Med. 187:427-432

Examiner
Signature

[Signature]

Date
Considered

8/18/05


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	09/644,668
Filing Date	August 24, 2000
First Named Inventor	Korman, Alan J.
Group Art Unit	1632 1644
Examiner Name	Unassigned
Attorney Docket Number	0146432-010510US

RECEIVED
OCT 02 2001
FBI CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

73	MATSUI (1999) J. Immunol. 162:4328-4335	
74	MCCOY et al. "Protective immunity to nematode infection is induced by CTLA-4 blockade," J. Exp. Med 186:183-187 (1997)	
75	NEUBERGER "Generating high-avidity human Mabs in mice," Nature Biotechnology 14:826 (1996)	
76	THOMPSON (1997) Immunity 7:445-450	
77	THOMPSON et al., Proc. Natl. Acad. Sci 86:1333-1337 (1989)	
78	WALUNAS et al. "CTLA-4 ligation blocks CD28-dependant T cell activation," J. Exp. Med 183:2541-2550 (1996)	
79	WALUNAS, et al., "CTLA-4 can function as a negative regulator of T Cell activation," Immunity. 1:405-413 (1994)	
80	WU et al., J Exp. Med. 185:1327-1335 (1997)	
81	YANG et al. "Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy," Cancer Research 59:1236-1243 (1999)	
82	YOKOCHI (1981) J. Immunol. 128:823	

Examiner Signature		Date Considered	8/18/03
--------------------	--	-----------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.